Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard D Finkelman

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 22, 2017
In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymesNancy Chen, Donghui Cui, Qing Wang, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 12, 2023
Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic HypoparathyroidismMishaela R Rubin, Natalie Cusano, Shaoming Yin, et al.
Journal of Periodontology|March 15, 2018
Letters to the EditorRichard D Finkelman, James Russell, Nelson Scarborough, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 25, 2009
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trialRosemary A Hannon, Glen Clack, Martin Rimmer, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjectsRichard D Finkelman, Tzung-Dau Wang, Yi Wang, et al.
Bone|January 17, 2012
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I studyRosemary A Hannon, Richard D Finkelman, Glen Clack, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2007
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal womenEugene V McCloskey, Rosemary A Hannon, Geza Lakner, et al.
JBMR Plus|July 17, 2023
A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for HypoparathyroidismSteven W Ing, Richard D Finkelman, Ping He, et al.
Journal of Periodontology|May 16, 2003
Efficacy of controlled-release subgingival chlorhexidine to enhance periodontal regenerationMichael S Reddy, Marjorie K Jeffcoat, Nico C Geurs, et al.
JBMR Plus|May 14, 2024
Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidismAliya A Khan, Lisa G Abbott, Intekhab Ahmed, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 22, 2017
In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymesNancy Chen, Donghui Cui, Qing Wang, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 12, 2023
Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic HypoparathyroidismMishaela R Rubin, Natalie Cusano, Shaoming Yin, et al.
Journal of Periodontology|March 15, 2018
Letters to the EditorRichard D Finkelman, James Russell, Nelson Scarborough, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 25, 2009
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trialRosemary A Hannon, Glen Clack, Martin Rimmer, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjectsRichard D Finkelman, Tzung-Dau Wang, Yi Wang, et al.
Bone|January 17, 2012
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I studyRosemary A Hannon, Richard D Finkelman, Glen Clack, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2007
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal womenEugene V McCloskey, Rosemary A Hannon, Geza Lakner, et al.
JBMR Plus|July 17, 2023
A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for HypoparathyroidismSteven W Ing, Richard D Finkelman, Ping He, et al.
Journal of Periodontology|May 16, 2003
Efficacy of controlled-release subgingival chlorhexidine to enhance periodontal regenerationMichael S Reddy, Marjorie K Jeffcoat, Nico C Geurs, et al.
JBMR Plus|May 14, 2024
Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidismAliya A Khan, Lisa G Abbott, Intekhab Ahmed, et al.
Pageof 3